Barclays lowered the firm’s price target on Hain Celestial to $7 from $8 and keeps an Equal Weight rating on the shares. The firm says the company’s weaker outlook begets more aggressive actions. North America was impacted not only by slower recovery in its infant nutrition and personal care units, which have been problematic for some time, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAIN: